October 13, 2023 (MLN): Haleon Pakistan Limited (PSX: HALEON) has planned to invest $10 million in its manufacturing facility at Jamshoro for the production of the Panadol base portfolio, including Panadol 500mg and Panadol Extra tablets, as disclosed in the company's filing with the local stock exchange.
The objective is to bring the latest manufacturing technology to Pakistan and enhance the production capacity to 8 billion tablets.
This will help the company to ensure smooth supplies of Pakistan’s largest pharmaceutical / Over-the-Counter medicine to the consumers and patients in need.
This investment comes in addition to the $2 million being spent on enhancing the manufacturing facility of our flagship brand CaC 1000 Plus to cater to the local needs and export opportunities that the company is currently working on.
It is important to mention that the Board of Directors (BoD) of the company has approved this investment and associated financing.
At the time of writing, the company’s share is being traded at Rs164.07, up by 11.45 rupees or 7.50% compared to the previous close.
HALEON is principally engaged in the manufacturing, marketing, and sale of consumer healthcare and over-the-counter health products.
